Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Vaxcyte (PCVX) priced offerings: 7.8M shares at $64 each, $500M in convertible notes due 2032. Proceeds (~$1B total) to fund clinical trials, manufacturing, and general corporate purposes. Offerings expected to close Oct 9, 2026. Notes carry 1.5% interest, convertible at $89.60/share.

Original reporting
Published Oct 7, 2026, 2:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 2:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PCVX
Bearish
high confidence
Mentioned
$PCVX
Relevance
9/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$PCVXBearishHigh
01

Why it matters

The $1 billion capital raise is the first major financing round for Vaxcyte, signaling confidence in its pipeline and setting a valuation baseline for future milestones.

02

Market read

The offering size and terms are material for investors; the news will likely drive immediate price action and set the stage for upcoming trial data releases.

03

What to watch

Potential conversion features of the notes and warrant over‑allotment options could further affect share count and price dynamics.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Vaxcyte is a clinical‑stage vaccine company advancing its PCV programs, including VAX‑31 adult and pediatric trials.

Company-level read

Ticker impact

$PCVXBearishHigh confidence
Context

Announced pricing of $1 billion concurrent public offerings of common stock, pre‑funded warrants and convertible senior notes.

Expected impact

potential short‑term pressure as the market prices in dilution, followed by upside if trial data materializes.

Evidence & confidence

Large primary capital raise is material news; dilution is immediate, but the funded pipeline offers upside catalysts.

Market effects

Provides a benchmark for biotech financing, may encourage similar raise activity in the vaccine sector.

Limited to US biotech investors; no broader regional effect.

Adds to overall biotech fundraising trends but unlikely to move broader indices.

Counterpoint

The dilution could outweigh near‑term pipeline upside, making the stock a short candidate until data de‑risking.

Key entities

  • Vaxcyte, Inc.

    Clinical‑stage vaccine innovator issuing equity, warrants and convertible notes.

  • Jefferies, Leerink Partners, BofA Securities, etc.

    Joint book‑running managers for the offerings.

Related articles

HighAI 9/10

Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals

Vaxcyte's VAX-31 pneumococcal vaccine met all primary endpoints in the phase 3 OPUS-1 trial, showing noninferior immune responses to existing vaccines and superior responses for unique serotypes. The trial enrolled 4,047 adults and demonstrated safety with mostly mild reactions. Vaxcyte plans to submit a BLA in 2028, with additional data expected in 2027. The vaccine aims to cover 86.7% of adult nonbacteremic pneumonia and 93.9% of adult IPD, addressing a significant healthcare burden.

$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

$PCVXHighAI 8/10

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.